Recommendations for Cerebrospinal Fluid Alzheimer'S Disease Biomarkers in The Diagnostic Evaluation of Mild Cognitive Impairment
Tarih
2017Yazar
Herukka, Sanna-Kaisa
Simonsen, Anja Hviid
Andreasen, Niels
Baldeiras, Ines
Bjerke, Maria
Blennow, Kaj
Engelborghs, Sebastiaan
Frisoni, Giovanni B.
Gabryelewicz, Tomasz
Galluzzi, Samantha
Handels, Ron
Kramberger, Milica G.
Kulczynska, Agnieszka
Luis Molinuevo, Jose
Mroczko, Barbara
Nordberg, Agneta
Oliveira, Catarina Resende
Otto, Markus
Rinne, Juha O.
Rot, Uros
Saka, Esen
Soininen, Hilkka
Struyfs, Hanne
Suardi, Silvia
Visser, Pieter Jelle
Winblad, Bengt
Zetterberg, Henrik
Waldemar, Gunhild
Üst veri
Tüm öğe kaydını gösterÖzet
This article presents recommendations, based on the Grading of Recommendations, Assessment, Development, and Evaluation method, for the clinical application of cerebrospinal fluid (CSF) amyloid-beta(1-42), tau, and phosphorylated tau in the diagnostic evaluation of patients with mild cognitive impairment (MCI). The recommendations were developed by a multidisciplinary working group and based on the available evidence and consensus from focused group discussions for 1) prediction of clinical progression to Alzheimer's disease (AD) dementia, 2) cost-effectiveness, 3)interpretation of results, and 4) patient counseling. The working group recommended using CSF AD biomarkers in the diagnostic workup of MCI patients, after prebiomarker counseling, as an add-on to clinical evaluation to predict functional decline or conversion to AD dementia and to guide disease management. Because of insufficient evidence, it was uncertain whether CSF AD biomarkers outperform imaging biomarkers. Furthermore, the working group provided recommendations for interpretation of ambiguous CSF biomarker results and for pre-and post-biomarker counseling. (C) 2016 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer's Association.